The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 2954-2964

  Lahser, Frederick C ^a   Bystol, Karin ^a   Curry, Stephanie ^a   McMonagle, Patricia ^a   Xia, Ellen ^a   Ingravallo, Paul ^a   Chase, Robert ^a   Liu, Rong ^a   Black, Todd ^a   Hazuda, Daria ^a   Howe, Anita Y M ^a   Asante Appiah, Ernest ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELBASVIR; GRAZOPREVIR; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MK-5172; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE; RIBAVIRIN;

AMINO ACID SUBSTITUTION; ARTICLE; CROSS RESISTANCE; DRUG POTENCY; EC90; GENE MUTATION; GENETIC DRIFT; GENETIC RESISTANCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; KINETICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPLICON CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA REPLICATION; WILD TYPE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; MUTATION; REPLICON;

ANTIVIRAL AGENTS; BENZOFURANS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; IMIDAZOLES; MUTATION; PROTEASE INHIBITORS; QUINOXALINES; REPLICON; RIBAVIRIN;

EID: 84964812653     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00051-16     Document Type: Article

References (34)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342. http://dx.doi.org/10.1002/hep.26141.
2. WHO. 2014. Guidelines for the screening, care and treatment of persons with hepatitis C infection. WHO, Geneva, Switzerland. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed 3 September 2015.
3. Gower Estes E, C, Blach S, Razavi-Shearer K, Razavi H. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45-S57. http://dx.doi.org/10.1016/j.jhep.2014.07.027.
4. Herbst DA, Reddy K. 2013. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Invest Drugs 22:527-536. http://dx.doi.org/10.1517/13543784.2013.775246.
5. Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. 2015. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 61:1798-1808. http://dx.doi.org/10.1002/hep.27724.
6. Deeks ED. 2015. Ombitasvir/paritaprevir/ritonavir plus dasabuvir: a review in chronicHCVgenotype 1 infection. Drugs 75:1027-1038. http://dx.doi.org/10.1007/s40265-015-0412-z.
7. Cento V, Chevaliez S, Perno CF. 2015. Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS 10:381-389. http://dx.doi.org/10.1097/COH.0000000000000177.
8. Summa V, Ludmerer S, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. 2012. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161-4167. http://dx.doi.org/10.1128/AAC.00324-12.
9. Kolykhalov A, Mihalik K, Feinstone SM, Rice CM. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 74:2046-2051. http://dx.doi.org/10.1128/JVI.74.4.2046-2051.2000.
10. Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, Barreiro P. 2011. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 66:1673-1686. http://dx.doi.org/10.1093/jac/dkr215.
11. Coburn CA, Meinke P, Chang W, Fandozzi CM, Graham DJ, Hu B, Huang Q, Kargman S, Kozlowski J, Liu R, McCauley JA, Nomeir AA, Soll RM, Vacca JP, Wang D, Wu H, Zhong B, Olsen DB, Ludmerer SW. 2013. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Chem Med Chem 8:1930-1940. http://dx.doi.org/10.1002/cmdc.201300343.
12. Macdonald A, Harris M. 2004. Hepatitis C virus NS5A: tales of promiscuous protein. J Gen Virol 85:2485-2502. http://dx.doi.org/10.1099/vir.0.80204-0.
13. McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, Asante-Appiah E, Neddermann P, De Francesco R, Howe AY, Lemon SM. 2014. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147:453-462. http://dx.doi.org/10.1053/j.gastro.2014.04.021.
14. Ross-Thriepland D, Harris M. 2015. Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on! J Gen Virol 96:727-738. http://dx.doi.org/10.1099/jgv.0.000009.
15. Rai DWL, Jiang X, Zhan P, Jia H, De Clercq E, Liu X. 2016. The changing face of hepatitis C: recent advances on HCV inhibitors targeting NS5A. Curr Med Chem 22:1860-1879. http://dx.doi.org/10.2174/0929867322666150209150920#sthash.6keCr4Wi.dpuf.
16. Harper S, McCauley J, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, Koch U, Petrocchi A, Holloway MK, Butcher JW, Romano JJ, Bush KJ, Gilbert KF, McIntyre CJ, Nguyen KT, Nizi E, Carroll SS, Ludmerer SW, Burlein C, DiMuzio JM, Graham DJ, McHale CM, Stahlhut MW, Olsen DB, Monteagudo E, Cianetti S, Giuliano C, Pucci V, Trainor N, Fandozzi CM, Rowley M, Coleman PJ, Vacca JP, Summa V, Liverton NJ. 2012. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 3:332-336. http://dx.doi.org/10.1021/ml300017p.
17. Yi M, Lemon S. 2004. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J Virol 78: 7904-7915. http://dx.doi.org/10.1128/JVI.78.15.7904-7915.2004.
18. Blight KJ, Kolykhalov A, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974. http://dx.doi.org/10.1126/science.290.5498.1972.
19. Ikeda M, Yi M, Lemon SM. 2002. Selectable subgenomic and genomelength dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficently in cultured Huh7 cells. J Virol 76:2997-3006. http://dx.doi.org/10.1128/JVI.76.6.2997-3006.2002.
20. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org/10.1053/j.gastro.2003.09.023.
21. Saeed M, Scheel T, Gottwein J, Marukian S, Dustin L, Bukh J, Rice CM. 2012. Efficient replication of genotype 3a and 4a hepatitisCvirus replicons in human hepatoma cells. Antimicrob Agents Chemother 56:5365-5373. http://dx.doi.org/10.1128/AAC.01256-12.
22. Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, Ralston R. 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 77:177-185. http://dx.doi.org/10.1016/j.antiviral.2007.11.010.
23. Gu Z, Graci J, Lahser F, Breslin JJ, Jung SP, Crona JH, McMonagle P, Xia E, Liu S, Karp G, Zhu J, Huang S, Nomeir A, Weetall M, Almstead NG, Peltz SW, Tong X, Ralston R, Colacino JM. 2013. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C virus NS4B protein. Antimicrob Agents Chemother 57:3250-3261. http://dx.doi.org/10.1128/AAC.00527-13.
24. Shimakami T, Welsch C, Yamane D, McGivern DR, Yi M, Zeuzem S, Lemon SM. 2011. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140:667-675. http://dx.doi.org/10.1053/j.gastro.2010.10.056.
25. Prichard MN, Prichard L, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 37:540-545. http://dx.doi.org/10.1128/AAC.37.3.540.
26. Prichard MN, Shipman C. 1990. A three-dimentional model to analyze drug-drug interactions. Antiviral Res 14:181-205. http://dx.doi.org/10.1016/0166-3542(90)90001-N.
27. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70:28-38. http://dx.doi.org/10.1016/j.antiviral.2005.12.003.
28. Guan Y, Sun H, Pan P, Li Y, Li D, Hou T. 2015. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations. Mol Biosyst 11:2568-2578. http://dx.doi.org/10.1039/C5MB00394F.
29. Fridell RA, Wang C, Sun JH, O'Boyle DR II, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. 2011. Genotypic and phenotypic analysis of variants resistant to hepatitisCvirus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54:1924-1935. http://dx.doi.org/10.1002/hep.24594.
30. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 83:4395-4403. http://dx.doi.org/10.1128/JVI.02352-08.
31. Tellinghuisen TL, Marcotrigiano J, Rice CM. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-379. http://dx.doi.org/10.1038/nature03580.
32. Pelosi LA, Voss S, Liu M, Gao M, Lemm JA. 2012. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor Daclatasvir. Antimicrob Agents Chemother 56:5230-5239. http://dx.doi.org/10.1128/AAC.01209-12.
33. Merck and Co., Inc. 2016. ZEPATIER™ (elbasvir and grazoprevir) tablets, for oral use. Prescribing information. Merck and Co., Inc., Kenilworth, NJ. https://www.merck.com/product/usa/pi-circulars/z/zepatier/zepatier-pi.pdf.
34. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. 2015. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163:1-13. http://dx.doi.org/10.7326/M15-0785.